Connect with us

stocks

Is Creative Edge Nutrition Inc (OTCMKTS:FITX) Gaining Investors’ Attention?

Published

on

Creative Edge Nutrition Inc (OTCMKTS:FITX) is moving lower in recent trading after the recent pop up. The stock continues to be one of the top most traded stocks on the entire OTCBB and boasts a very loyal following of investors.

FITX announced on November 19 their intention to Spin Off Canadian Wholly-Owned Subsidiary, CEN Biotech Inc. as well as the resignation of the entire board of directors and officers in the Company.

The news which completely changes the course of FITX moving forward lacks much important information and clarification and has left shareholders confused. It does state that current shareholders will both keep their shares of FITX and receive additional shares of the newly formed publicly traded company. The share distribution will be on a “pro rata basis” based on the number of FITX shares owned; more on this later.

Creative Edge Nutrition Inc (OTCMKTS:FITX) is a Nutritional Supplement Company that entered the pot business at the end of last year when they leased a six acre site with buildings in the Town of Lakeshore, Ontario, Canada.

At the time the Company established a partially owned subsidiary CEN Biotech, Inc. with the sole purpose of obtaining a licensure to build Medicinal Marijuana facilities adhering to all local legal requirements.

The plan was to build a 58,000 sq. ft. building to grow pot and make the property the largest, most advanced medical marijuana grow facility on earth. CEO Bill Chaaban said they plan to “‘Eventually expand that facility to more than 1 million square feet on multiple floors and within five years grow 1.3 million pounds of pot annually. That would translate to $5 billion a year’ in revenue”

Back in November 2013 FITX announced ”it has broken ground to start the build-out” This news was the initial catalyst that would drive FITX from illiquid in the subs to over a dime at its highs and easily the top most traded stock on the entire OTCBB. The problem has been from the beginning that the Town of Lakeshore wants nothing to do with FITX and has been dogging the Company on zoning since day one.

There has been incredible confusion on the issue much of it instigated by former CEO Bill Chaaban who continued to issue press suggesting the project was moving ahead full steam even as the Company lacked such basics as obtaining a license from MMPR (Medical Marihuana Purposes Regulations) and required municipal approval from the Town of Lakeshore.

On November 6 the Town of Lakeshore said on their website that ‘’the subject North Rear Road properties are zoned and designated Agricultural and the current structures are consistent with the designation and zone.  However, the growing or processing of medical marihuana at these sites would not be permitted under their current zoning.  An applicant would be required to apply for a Re-zoning of the site. They are not ‘grandfathered’ under the Council amendment.’’

We have the Inside Scoop on FITX, to find out what it is Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

There seems to be some shareholders that are so vested in the idea that they want to continue to believe the Lakeshore project will happen touting minutes from a Lakeshore council meeting back in November of last year that says that FITX does have the correct zoning.

FITX announced on November 19 their intention to Spin Off Canadian Wholly-Owned Subsidiary, CEN Biotech Inc. as well as the resignation of the entire board of directors. They announced Mr. James Robinson, a noted entrepreneur in the dietary nutrition space as the new CEO and said they plan to focus on Nutrition.

Upon completion of the spin-off, all shareholders of Creative Edge Nutrition, Inc. will retain their shares in Creative Edge Nutrition while additionally getting shares in CEN Biotech Inc., which will be a new publicly-traded company. The distribution of CEN Biotech Inc. shares will be on a pro rata basis to the Creative Edge Nutrition shareholders based on the number of shares of Creative Edge Nutrition shares owned by each shareholder.

The ‘entire board of directors’ that resigned from the nutritional division are now the board of directors of CEN Biotech, the marijuana division.

FITX has built a massive following that includes 12,500 followers on Facebook, 1,500 followers on Investors hub and 4,700 followers on Seeking Alpha.

We have a Monster Pick Coming. Subscribe Right Now!

Like no other pot stock FITX was the most successful in capturing the imaginations and pocketbooks of small cap investors. At its height the stock was almost like a cult with shareholders selling t-shirts that said “FITX-Long” or “I-Billieve” (as in president and CEO of FITX, Bahige “Bill” Chaaban).

Currently trading at a $65 million market valuation FITX has never traded on fundamentals and it’s certainly not about to start now. As new CEO James Robinson takes the helm, shareholders are left wondering what happened in Lakeshore, Ontario.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in FITX either long or short and we have not been compensated for this article.

Continue Reading
5 Comments

5 Comments

  1. Scienitst

    December 15, 2014 at 5:02 pm

    The need to immediately legalize Marijuana nationally is one of the most pressing moral issues of our time.

    More and more present and former members of law enforcement agree, and have formed a rapidly expanding group of current and former police officers, FBI, DEA, and customs agents, and prosecutors, from all over the world, called LEAP — Law Enforcement Against Prohibition.

    Like the majority of Americans, I strongly support the immediate, complete legalization of Marijuana.

    But as a Scientist with a strong interest in Cancer research, I feel even more strongly about the need for its immediate legalization of it for Medical use, and the need to ensure that no Cancer patient is denied it, because I’m so impressed with its benefits for Cancer patients.

    I urge everyone reading this to PLEASE call and email the Attorney General, the press, Congress and the President today.

    Medical Marijuana not only helps with Cancer therapy, seizures, PTSD and chronic pain, but has helped countless Americans, including countless veterans, stop using Alcohol, and hard drugs, both legal and illegal ones.

    Every minute an American dies of Cancer.
    Every 19 minutes an American dies of a prescription drug overdose.
    Many vets become addicted to prescription opiates and die from them.

    NOBODY has ever died from smoking too much pot.

    Cancer patients are seeing remarkable results using high dose Medical Marijuana oil, in many cases achieving complete remission, even for stage 4 cancers, and every Cancer patient that uses Marijuana to ease their suffering benefits greatly from doing so.

    It is immoral to leave Marijuana illegal, for anyone, for even a second longer.

    For Cancer patients, its a matter of life and death.

    Cancer patients can’t wait.

    Medical Marijuana has an unmatched safety profile, and for people who suffer from so many diseases of so many kinds its a medical miracle, and the scientific evidence behind it is rock solid.

    For example, Medical Marijuana encourages apoptosis and autophagy of Cancer cells, while leaving normal cells untouched, is anti-angigogenic, anti-proliferative, and is anti-angiogenic.

    Its also synergistic with chemotherapy and radiation therapy, making both more effective.

    For many Cancer patients its meant the difference between life and death.

    For everyone else, its a far safe alternative to Alcohol, and infinitely safer than Cigarettes.

    Either take them off the market too, or legalize Marijuana right now.

    2016 is too far away, Its too long to wait. Every year we lose more Americans to Cancer than died in WWII.

    Between now and the 2016 elections, roughly 1 MILLION Americans will die of Cancer.

    And Its a horrible way to die.

  2. James

    December 16, 2014 at 8:23 am

    CEN in September put a press release out showing the Town of Lakeshore knew of the intentions and making claim the company did have the correct zoning. They went so far as to include the minutes from the town council meeting and highlighting the relevant sections in yellow highlighter.

    The company is correct but like many things, the devil is in the details. The company failed to mention that yes, they were in an Agricultural Zone but that zone also was zoned as Value Added. In short, this meant that crops grown on that site could have small amounts processed on site but they would be limited to 6000 square feet and five employees per shift.

    Of course investors, protecting their interests continued to twist the truth by stating that Health Canada does not allow for processing of medical marijuana and they are correct but again, the devil is n the details. Under the Value Added definition, packaging also is included so because CEN would be packaging and shipping to patients, they were caught under the Value Added clause. To get relief from these restrictions the company would have to file an zoning amendment application. Part of the process of the application is to engage affected residents and the town in a dialogue of negotiation and understanding as the process of building takes place.

    For example, the company would have to over a two week period, contact all residents and others affected within a defined distance from the facility (WHICH THEY DID NOT DO) as well as provide to the town a detailed plan not only of the activities on that site, but what utilities would be required in terms of water, sewage, gas, electrical (WHICH THEY DID NOT DO) in order for the town to determine if those activities could even take place.

    In short the company informed the town of their intent but failed to take the steps necessary to determine if those activities would be possible on that site. There is a difference between having the correct zoning (WITH RESTRICTIONS IN THIS CASE) and their existing the infrastructure to support the activities.

    Throughout the winter and spring and into summer the company Facebook page would tolerate no discussion on the zoning issue stating only that it had all municipal approvals. CEN quietly submitted a zoning amendment application to the town recognizing their need to do so. Two previous attempts by Bill’s cousin Jim, who receives monthly lease payments from the company failed to change the zoning to accommodate two different businesses on that same site. Despite the fact town and country officials were at the press conferences for both Jim’s movie studio and Bill’s largest medical mj facility in the world, issues remained blocking the progress. The town acknowledged receiving the zoning amendment application but noted it was deficient and was not considered.

    So rather than engage the nearby residents and the town prior to the construction or at least during the construction of the second building which is classed as a pole barn on the building permits filed by Bills cousin Jim, they completed the structure with zero input from nearby residents.

    There was no official engagement of the residents the way there would have been HAD THE COMPANY FILED THE ZONING AMENDMENT APPLICATION BACK IN DECEMBER OF 2013 OR EARLY 2014 NOR WITH THE TOWN IN ORDER TO FACILITATE THE TOWN DETERMINING IF THEIR NEEDS COULD BE MET UTILITY WISE.

    It seems a bit of a twist on Field of Dreams – if we build it, they have to approve us. Oh yes, legal non-conforming. That might work, might, if they get the license from HC prior to the zoning amendments referenced in your story coming into force which may be announced by Essex County. Had the company filed the zoning amendment application back when they knew they would have to, a lot of this mess could have been avoided and the picture much clearer.

  3. Art

    December 16, 2014 at 9:32 am

    “FITX announced on November 19 their intention to Spin Off Canadian Wholly-Owned Subsidiary, CEN Biotech Inc. as well as the resignation of the entire board of directors. They announced Mr. James Robinson, a noted entrepreneur in the dietary nutrition space as the new CEO and said they plan to focus on Nutrition.”

    Did you purposely leave out the fact that the ‘entire board of directors’ that resigned from the nutritional division are now the board of directors of CEN Biotech, the marijuana division? Just wondering.

  4. Alex Ryan

    December 16, 2014 at 10:02 am

    Thanks for the excellent information James. Art there was no intenetion to leave anything out. I have updated the article to the effect that ” ‘entire board of directors’ that resigned from the nutritional division are now the board of directors of CEN Biotech”

    We write about a lot of stocks and always want to provide the best information possible. I will certainly try to incorporate the information that James has shared and anything anyone else would care to share on FITX in our next article on the Company.

    Post any info on FITX here.

  5. Ralph E.

    December 16, 2014 at 10:46 am

    You Mention that FITX has never traded on the fundamentals. The reason is that when some one looks at the fundamentals they see a company that has a Board of Directors Like no other, with world recognized leaders in Medicine, and Global Finance. A company that is positioning itself to be the leader in many industries that support the Legal Cannabis industry, as well as that industry itself.
    The current valuation is many times less then the company’s true value, making it a must buy for anyone who understands the importance of Value.
    A Fundamentals trader would not trade in this, they would Invest. This is a Long Hold for anyone who recognizes that FITX, and The Spin-off, Cen Biotech is poised to be at the leading edge of this whole new industry.

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

Clean Vision Corp (OTC: CLNV): Overcoming the Plastic Waste Crisis

Published

on

Clean Vision Corporation (OTC: CLNV) has experienced several interesting developments recently, but it hasn’t noticeably influenced the market with any substantial gains. Nonetheless, we believe it’s worth providing an update on the company given it’s been a few months since our last mention. In today’s discussion, we’ll explore a variety of updates and their significance, with aim of providing insight on what to expect for 2024.

Background:

Clean Vision is led by Dan Bates, and their goal is to tackle the global plastic waste crisis head-on. Their wholly owned subsidiary, Clean Seas, has developed the Plastic Conversion Network (PCN), a groundbreaking technology aimed at diverting millions of tons of waste plastic from landfills, incineration, and oceans. The PCN converts this plastic feedstock into clean fuels and green hydrogen, significantly reducing reliance on fossil fuels and lowering the carbon footprint.

For a brief 2 minute overview on the company, feel free to reference the video CLNV’s subsidiary put together on YouTube. Here’s the link.

Clean Seas utilizes proven pyrolysis technology to produce environmentally friendly products, which are sold to multinational petrochemical companies, driving the circular plastic economy. Operational PCN facilities are already in place in Morocco and India, with additional conversion facilities in development across West Virginia, Arizona, and Southeast Asia. Long-term feedstock supply agreements exceeding one million tons of waste plastic annually have been secured at no cost.

Their recently trademarked brand, AquaH®, is produced in their PCN. According to the release, it offers a differentiated green hydrogen product from carbon-neutral sources. Currently, hydrogen is predominantly produced through methods that involve fossil fuels, which of course contributes to global carbon emissions. Furthermore according to Deloitte’s 2023 global green hydrogen outlook, this could be a $1.4T annual market by 2050.

$65 Million Plastic Conversion Facility:

CLNV is making big moves in West Virginia and according to the release on October 24th, 2023, they’ve brought in some serious players—CDI Engineering Solutions and ERM—to help out with their Clean-Seas West Virginia project.

CDI has over 70 years of experience integrating engineering, design, project support, procurement and construction management services to the energy, chemicals and electrical infrastructure markets.

ERM is the world’s largest advisory firm focused solely on sustainability, offering environmental, health, safety, risk and social expertise for more than 50 years with more than 8,500 dedicated professionals operating across 40 countries.

The plan is to kick things off in 2024, turning 100 tons of plastic every day into recycled plastics and clean fuels. It’s a hefty project with a $65 million investment, creating over 200 jobs initially. And they’re not stopping there—they want to scale up to 500 tons of plastic per day over time.

West Virginia Governor Jim Justice is also on board, throwing over $12 million in state incentives to support the project.

Governor Jim Justice made a reference to Clean Seas in his state of the union address. If you want to catch the mention, go to 34:15 in the video. The three minutes leading up to it are also worth reviewing.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Launches Global Operations:

CLNV made another significant advancement, planning to launch waste plastic conversion facilities in the European Union, Eastern Europe, and Southeast Asia. This will be accomplished through their new subsidiary, Clean-Seas Partners UK Limited (CS-UK), who of course shares the same vision of creating sustainable solutions to the global plastic pollution crisis.

Under the leadership of Managing Director Shaun Wootton, CS-UK will play a crucial role in strategic project development and investment facilitation, leveraging established relationships in the Middle East, Southeast Asia, and Europe.

To fortify effective governance and strategic direction, CS-UK is assembling a distinguished board with internationally recognized figures in banking, sustainability, and energy. This approach aims to have a diverse and experienced board guiding CS-UK in realizing its vision of promoting sustainability and environmental stewardship across diverse regions.

$340 Million Bond Offering:

CLNV even announced they partnered with a global advisory firm, Grant Thornton, to issue up to $340 million in Green Bonds. This is the world’s sixth-largest network of independent accounting and consulting firms, employing 62,000 people in more than 130 countries and had revenues of $6.6 billion in 2021. These bonds will fund the expansion of Clean Vision’s Plastic Conversion Network (PCN) under the “Clean-Seas” initiative worldwide, aimed at combatting plastic pollution on a global scale.

With the Green Bond’s net proceeds, CLNV plans to deploy at least six plastic waste conversion lines globally, with strategic locations in West Virginia, Arizona, Southeast Asia, and expansion in Morocco. The Green Bond is also expected to attract environmentally conscious investors, setting a new standard for corporate responsibility.

$15M Government Loan:

Lastly, under the capable management of Huntington Bank, CLNV has recently secured a $15 million government loan. What sets this apart is that the loan is FORGIVABLE.

A forgivable loan is a type of loan where the borrower is not required to repay the borrowed amount under certain conditions. Typically, these conditions are related to the borrower meeting specific criteria, such as using the funds for approved purposes, maintaining certain employment levels, or achieving predetermined goals. If the borrower fulfills these conditions, the loan is forgiven, and they are not obligated to repay the borrowed amount. Forgivable loans are often used as an incentive or support for specific activities, such as job creation, small business development, or other initiatives that contribute to economic growth or community welfare.

Not to mention it won’t result in any dilution for shareholders. This is an unexpected and uncommon accomplishment for an OTC company. Securing a government loan of this size without any dilution is truly impressive.

Conclusion:

CLNV has made impressive strides tackling the global plastic waste crisis, especially given their valuation of merely $22.65 million. The team has swiftly achieved key objectives, including a $65 million plastic conversion facility in West Virginia, global expansion through Clean-Seas Partners UK Limited, a $340 million Green Bond Offering, and a remarkable $15 million forgivable government loan. The vast $1.4 trillion market they’re tapping into offers an interesting opportunity with current indicators looking positive. Nevertheless, it’s crucial to acknowledge that there is still significant work ahead, and the team needs to maintain consistent execution to turn this potential into a reality.

We will update you on CLNV when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by pasja1000 from Pixabay

Continue Reading

BioPharma

Bioxytran (OTCMKTS: BIXT) Peer-Review Published Showing Functional Cure for COVID-19

Published

on

On the cusp of a cure for COVID, one of the most promising yet under-the-radar biotech stocks on the OTC is generating much well-deserved buzz in the scientific community and is poised to go viral.

Bioxytran Inc. (OTCMKTS: BIXT) over the weekend had their phase 2 top-line results published in the peer-reviewed journal “Vaccines.” There is a not-so-subtle tinge of irony in that name because while their drug is nothing like a vaccine, there is no doubt about its efficacy– 100% PCR negative rate by day 7 versus 6% in placebo.  The medical journal article was titled “An Oral Galectin Inhibitor in COVID-19 – A Phase 2 Randomized Controlled Trial.” This is a landmark journal article because – until now – only one other drug, Harvoni, had equaled a 100% responders rate in the past decade.  Harvoni ultimately ended up being a cure for Hepatitis C Virus.

At this point in Bioxytran’s drug development pipeline, it essentially has a functional cure for COVID-19 that simply needs a pivotal phase 3 trial to show the true extent of their discovery.  Their drug is a galectin antagonist, which neutralizes the now infamous spike proteins by placing a carbohydrate sheath over the spikes making attachment to the cell impossible. The carbohydrates binding grip is so tight on the virus that it carries it around in the blood until it is eventually filtered out by the liver and excreted. 

If solving the pandemic wasn’t enough, the company recently reported that in vitro studies suggest the drug would be effective in Influenza and RSV.  Yet despite the fact that this one drug could seemingly end upper respiratory infections, which most of us refer to as a “common cold,” it has a nominal market cap of just $50 million.       

For the past three months, BIXT has been teasing this peer-reviewed article as a catalyst and a major value inflection point for the company. Despite that, investors haven’t gotten the hint, and have been steadily selling into this inflection point. Even though the company has yet to report it in a press release, the scientific community is understandably going crazy over it. Investors, however, are seemingly oblivious to the viral traffic and simply not paying attention to the sheer magnitude of the discovery–a functional cure for COVID and the methodology to seemingly combat any virus.  

One of the reasons peer review is so important for a biotech is that major media outlets won’t touch the science without it. With its publication, this article means that BIXT now has an opportunity to tell its story on network media. The biggest risk that investors now face in BIXT is FOMO, driven by an unexpected media appearance that ushers unbridled buying into the name and leaves tepid investors chasing up.   

If the article itself wasn’t enough, their peer-reviewed article was picked up by a major biotech influencer on Twitter, quickly garnering more than 100k hits.  The influencer, Chris Turnbull, summarized the article highlighting key points like the rapid viral clearance in 3 days through entry inhibition and suggested the ideal use is when you know you were exposed. He hammered the point that ProLectin-M was for standard-risk patients and that Paxlovid was for high-risk groups with at least one medical condition.   

This discovery changes the COVID landscape permanently.  Multi-billion dollar antiviral drugs like Paxlovid and Lagevrio can’t hold a candle to the viral clearing power of BIXT’s galectin antagonist. Looking at the Twitter account of BIXT Chief Commercial Officer Michael Sheikh, it’s clear that there are some ongoing discussions with big pharma that have not yielded any fruit. But big pharma may not be their only option. BIXT has also said they are looking to partner with companies with large cash balance sheets.  Both galectin antagonist companies Galectin Therapeutics (NASDAQ: GALT) and Galecto Bioscience (NASDAQ: GLTO) fit the profile and are the subject of a number of relatively supportive tweets by Sheikh.  Sleuthing Sheikh’s LinkedIn profile reveals hardcore evidence of that sort of dealmaking with clusters of top executives in certain companies and networking, which suggests significant activity among their larger Galectin-focused peers.  In an emerging growth interview, the CCO did say that he got a lot of business cards and was networking.      

There exists a huge chasm between the current market cap and what it ought to be given that it successfully completed a phase 2 and nailed the endpoint with a perfect score. The CCO described in an Emerging Growth video how valuations work and a number of comparables in the $500 million range for a number of disease indications that BIXT is developing.  The stock has a very tiny float of 19 million with an OS of 123 million.  This represents a float of 15% and insiders own over 60%.  There is no dilution from the convertible notes as they have company-friendly terms that allow up to 5% conversion into restricted common stock. In an Emerging Growth interview a couple of months ago, the CCO acknowledged the stock’s current challenge, indicating a legacy seller was responsible for half the daily volume and was almost gone. In early March after a ZeroHedge article was published, the stock went on a record run to $1.05 in a matter of minutes before short forces brought it back down. On March 7th it looks like the seller ran out of inventory for the day and the demand just lifted the stock price allowing it to go through a short period of natural price discovery.  The long-term legacy seller seems to be at the end of his block, which means any news announcement could push the stock higher.    

Low-Risk Explosive Reward Profile

There is no doubt that BIXT has incredible potential yet the stock continues to languish. With the anemic volume, it’s very difficult to diagnose what the root cause is for the disconnect from the comparable valuations established by big pharma in the $500 million region and BIXT’s current $50M cap. If one article that generated a little bit of buying pushed it to the brink of explosiveness, perhaps there is more stock from this legacy seller that is still controlling the narrative.  

Upcoming Catalysts

For the investor with a longer-term view, BIXT represents a safe place to park funds for explosive returns.  The upcoming catalysts are a dosing of patients in India for the dose optimization trial, a potential IND from the FDA, and of course, the announcement of the peer-reviewed journal article.  While it’s uncertain which catalyst will send the stock into overdrive it’s abundantly clear this is one of the most undervalued stocks in OTC.   

Pound-for-Pound Comparison of Paxlovid and PLM

Paxlovid also helped lower the length of time people with underlying medical conditions were infectious.  However, Paxlovid is not a very effective drug and is walking a tightrope with respect to its approval as more and more real-world data reveals their toxicity.  

Here is a chart capture from the company’s latest scientific webinar that shows a side-by-side comparison for illustrative purposes.  The charts show that Paxlovid can barely turn 30% of the patients PCR negative by day 20 whereas a majority of the PLM patients were PCR negative on day 3.  This is an absolute game-changer in controlling the pandemic.  The other thing that this peer-reviewed journal highlighted is that the symptoms were eliminated and without those symptoms, people were unlikely to develop Long COVID.  It’s very reasonable to believe that PLM stops Long COVID due to its mechanism of action as well as the fact that it appeared to eliminate symptoms in this trial, as seen in the picture below.  While it’s nice that Paxlovid stops hospitalization and death, PLM takes it to a new level by making you feel better faster and eliminating the risk of Long COVID.

Investment Summary

Bioxytran is not only sitting on a solution for COVID and a possible end to the pandemic, but it appears they can also treat Long COVID and a number of viruses.  All this information is out there in the public domain and investors seem to be sitting on their hands waiting for something more to happen.  It’s unclear what that trigger will be.  Will it be a video interview on major media? Will it be the IND announcement from the FDA? Or will it be an explosion of XBB1.16 cases in India whereby they fast-track the PLM development in the country?  Whatever the catalyst, the risk/ reward scenario on BIXT is one of the best in all of the OTC.  The small float coupled with the lack of an S-1 on file eliminating the risk of immediate dilution bodes well for either a long-term or medium-term investor.  

Investors need to ask themselves if they could have invested in penicillin knowing the impact it was going to have last century would they have dived in?  Investors are facing a similar scenario with PLM.  This is perhaps the biggest antiviral discovery of the century which amounts to a functional cure for COVID and possibly other viruses.  Will investors stay on the sideline because some grumpy shareholder is selling not allowing immediate price discovery or will they step up to secure their place in history?  Time will tell, but what is certain is that PLM will save an immeasurable amount of lives and take away untold suffering if it can navigate its way to regulatory approval. But while BIXT may be curing Covid, there is still only one cure for FOMO. Investors would do well to stop waiting on the sidelines to enter or affirm their positions before this game-changing anti-viral goes viral.     

Disclosure: MicroCap Daily and its owners do not have a position in the stocks posted and have posted this article for free without editorial input. This article was written by a guest contributor and solely reflects his opinions.     

Continue Reading

stocks

Frontera Group Inc (OTCMKTS: FRTG) Breakout as Co Commences Commercial Sales of Immersient Following IntelliMedia Networks IP Acquisition

Published

on

Frontera Group Inc (OTCMKTS: FRTG) is making an explosive move northbound in recent trading and is currently under heavy accumulation but still unnoticed by most investors. This is changing quickly as some heavy hitters have jumped on FRTG. The Company is only trading for a $2.7 total valuation with a float of just 3,280,000 FRTG is an SEC filer looking to uplist to OTCQB with a 10k coming out any day. From current levels FRTG has a lot of room to grow. Recently Frontera signed a marketing agreement with Long Side Ventures LLC, following an earlier marketing agreement with Stephen Steen on April 27, 2022. 

Earlier this year FRTG acquired intellectual property rights from Intellimiedia Networks, Inc., for $5 million in cash and 20 million shares of FRTG.  According to the 8k FRTG plans to raise $12 million by year end 2023. Essentially, Intellimedia turned over its assets and Intellectual Properties to Frontera, as Frontera has the platform in place to maximize the value of the purchased IP. Intellimedia Networks is a US and India-based technology company that designs and deploys cloud platforms and applications that create immersive experiences. Intellimedia’s award-winning products utilize AR, VR, and AI to enhance media, training, education, virtual event broadcasting, real estate, and other applications. Frontera brought on business execs Teodros Gessesse and Darshan Sedani. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Frontera Group Inc (OTCMKTS: FRTG) is a strategic acquirer of intellectual property and revenue-generating companies in the technology and human capital markets. It is developing and executing an aggressive, four-tier acquisition and implementation strategy intended to provide substantial increases in profitability to its acquisitions in industries which possess traditionally low and stagnant EBITDA multiples. The Company has identified and is currently pursuing several revenue-generating acquisition targets. 

Earlier this year FRTG acquired intellectual property rights from Intellimiedia Networks, Inc., for $5 million in cash and 20 million shares of FRTG. According to the 8k FRTG plans to raise $12 million by year end 2023. Essentially, Intellimedia turned over its assets and Intellectual Properties to Frontera, as Frontera has the platform in place to maximize the value of the purchased IP. Intellimedia Networks is a US and India-based technology company that designs and deploys cloud platforms and applications that create immersive experiences. Intellimedia’s award-winning products utilize AR, VR, and AI to enhance media, training, education, virtual event broadcasting, real estate, and other applications.  

In connection with the acquisition Teodros Gessesse was appointed as the Chief Marketing Officer of the Company. Mr. Gessesse’s initial annual base salary will be $150,000. Mr. Gessesse will be eligible to receive a quarterly bonus as determined by, and within the sole discretion of, the BOD and was granted 23,500,000 shares of FRTG. Also, Darshan Sedani was appointed as the Chief Visionary Officer of the Company. Mr. Sedani’s initial annual base salary will be $150,000. Mr. Sedani will be eligible to receive a quarterly bonus as determined by, and within the sole discretion of, the BOD and was granted 31,500,000 shares of FRTG. The deal closed on August 17. 

To Find out the inside Scoop on FRTG Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

FRTG

 

In June FRTG released the 3.0 version of its Mixie Holoport immersive reality framework with Extended Reality (XR) support (“Mixie Holoport XR”). Mixie Holoport XR is a National Association of Broadcasters (NAB) Product of the Year award winner, setting the benchmark for immersive realism in Augmented Reality (AR), Mixed Reality (MR), and Virtual Reality (VR) applications. Frontera recently acquired the Mixie Holoport IP to enhance Metaverse business applications. 

Frontera also launched its Mixie AI 2.0 powered live video broadcasting solution that will be targeting automated broadcasting applications. Frontera’s recent acquisition of Intellimedia’s Mixie suite of solutions has provided Frontera with a cutting-edge mix of media technology, learning and training platforms, and event broadcasting technologies that position the company at the technology forefront of a new wave of immersive and engaging technologies that continue to redefine applications. Intellimedia’s Mixie AI 2.0 solutions were utilized for Cricket AI Tata Open Tournament and the ISSF Shooting World Championship to simplify and automate the capture, analysis, discovery, and broadcast of both events. The resulting professional broadcast quality and dramatic cost reduction have become a wake-up call for both organizations to stage and broadcast future events.  

Earlier this month FRTG reported it has commenced commercial sales and marketing efforts of Immersient, the intellectual property which was acquired from IntelliMedia Networks, Inc. and formerly sold under the Mixie brand name. Now sold and marketed under the Immersient brand, Frontera’s cloud media platform connects content producers, educational institutions, and event producers with participants and viewers, delivering immersive, personal experiences, interactive participation, existing device compatibility, familiar user conventions, and reliable, “always available” service. The Immersient cloud media platform allows its clients to focus on their core businesses, knowing their end users are enjoying state-of-the-art experiences. With its frictionless device and network independent approach to immersive virtual, augmented, and mixed reality environments, Immersient delivers next-generation group collaboration and communications, interactive distance learning and training, and virtualized events, meetings, expos, conferences, and trade shows. 

For More on FRTG Subscribe Right Now!

Currently trading at a $2,7 million market valuation FRTG has 55,563,482 shares outstanding and just 3,280,000 shares in the float. The Company has a clean balance sheet and recently filed a 10Q with a 10k on the way and looking to uplist to OTCQB. FRTG is an exciting story developing in small caps; earlier this year FRTG acquired intellectual property rights from Intellimiedia Networks, Inc., for $5 million in cash and 20 million shares of FRTG.  According to the 8k FRTG plans to raise $12 million by year end 2023. Essentially, Intellimedia turned over its assets and Intellectual Properties to Frontera, as Frontera has the platform in place to maximize the value of the purchased IP. Earlier this month FRTG reported it has commenced commercial sales and marketing efforts of Immersient, the intellectual property which was acquired from IntelliMedia Networks, Inc. and formerly sold under the Mixie brand name. Now sold and marketed under the Immersient brand, Frontera’s cloud media platform connects content producers, educational institutions, and event producers with participants and viewers, delivering immersive, personal experiences, interactive participation, existing device compatibility, familiar user conventions, and reliable, “always available” service. The stock is currently under heavy accumulation, with big momentum, a little float and some well-known investors jumping on board.  We will be updating on FRTG when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with FRTG.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in FRTG either long or short and we have not been compensated for this article.

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.